Apatinib Second Line Treatment for Advanced Osteosarcoma and Soft Tissue Sarcomas ,Openting ,Single Center, One-armed Clinical Study.
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT03163381|
Recruitment Status : Unknown
Verified May 2017 by YaoWeitao, Henan Cancer Hospital.
Recruitment status was: Recruiting
First Posted : May 23, 2017
Last Update Posted : May 23, 2017
|Condition or disease||Intervention/treatment||Phase|
|Osteosarcoma, Advanced||Drug: Apatinib||Phase 2|
|Study Type :||Interventional (Clinical Trial)|
|Estimated Enrollment :||40 participants|
|Intervention Model:||Single Group Assignment|
|Masking:||None (Open Label)|
|Official Title:||Apatinib Second Line Treatment for Advanced Osteosarcoma and Soft Tissue Sarcomas ,Openting ,Single Center, One-armed Clinical Study.|
|Actual Study Start Date :||April 11, 2017|
|Estimated Primary Completion Date :||October 11, 2017|
|Estimated Study Completion Date :||April 11, 2019|
Apatinib 500mg/d from day 1 to day 28, repeated every 28 days until progressive Disease(PD) .
Apatinib 500mg,po,qd,medicine to disease progression.
- progress free survival [ Time Frame: 6 months ]time from study drug treatment to tumor progress
- overall survival [ Time Frame: up to 24 months ]Time from study drug treatment to die
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03163381
|Contact: Weitao Yaoemail@example.com|
|Henan cancer hospital||Recruiting|
|Zhengzhou, Henan, China, 450000|
|Contact: Jing Ding 0371-65588251|